Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 67th Annual Health Research Conference organized by the Caribbean Public Health Agency (CARPHA), taking place from April 27-29, 2023, in the Bahamas. This conference is the largest and longest-running health research event in the Caribbean and Latin America, aimed at promoting collaboration among health scientists and policymakers.
Co-Diagnostics will showcase its infectious disease products, including the upcoming Co-Dx PCR Home™ testing platform, which is currently under FDA review and not yet available for sale. The company has actively participated in CARPHA conferences since 2016 and is well-regarded for its innovative diagnostics technologies.
Co-Diagnostics, Inc. (NASDAQ: CODX) announced its participation in the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The ECCMID is a key event in infectious diseases, attracting over 14,000 attendees and offering a hybrid format for greater accessibility. Co-Dx aims to connect with international customers for its real-time PCR products, including the upcoming Co-Dx PCR Home™ platform, which is currently under FDA review and not yet for sale. Visitors can find the company at Booth B4-04 to learn more about its innovative diagnostics technologies, which focus on nucleic acid detection and analysis.
Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its CEO, Dwight Egan, will deliver the keynote presentation on the Co-Dx PCR Home™ testing platform at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23, 2023, in London. The company will also host a booth at the event. The Co-Dx PCR Home™ platform is currently undergoing clinical evaluations subject to FDA review and is not yet available for sale. This conference aims to bring together experts in the field of diagnostic research.
Co-Diagnostics, Inc. (NASDAQ: CODX) is set to participate in the 10th Gene Quantification Event from March 20-24, 2023, at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Scientific Advisory Board, will present on 'At-Home PCR Testing for SARS-CoV-2' on March 20 at 2:00 PM. The presentation will highlight the feasibility of the Co-Dx PCR Home™ testing platform for at-home infectious disease diagnosis. This platform is under FDA review and is not yet for sale. The event will cover various topics including SARS-CoV-2 and liquid biopsy, featuring an industrial exhibition showcasing advancements in molecular diagnostics.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported a revenue of $34.2 million for the full year 2022, significantly down from $97.9 million in 2021, primarily due to reduced demand for Logix Smart™ COVID-19 tests. The company faced an operating loss of $27.0 million, compared to an operating income of $46.1 million the previous year. Net loss totaled $14.2 million, translating to a loss of $0.45 per diluted share. Despite these challenges, Co-Diagnostics initiated clinical evaluations for its Co-Dx PCR Home™ platform, signaling a shift towards at-home diagnostics. The company also repurchased 3.9 million shares for approximately $14.2 million.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its fourth quarter and full year 2022 financial results on March 16, 2023, after market close. A conference call and webcast are scheduled for that day at 4:30 p.m. EDT, featuring CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Interested participants can join the call via domestic and international lines. A replay will also be available on the company's website for those unable to attend live. Co-Diagnostics specializes in molecular diagnostics and offers innovative technology for nucleic acid analysis.